IP Library Granted Patent US 12,295,395
Granted Patent B2
US 12,295,395 · App. 17/554,998 · Granted May 13, 2025

Liquid concentrate composition

Inventors: Mary Elizabeth Quinlan (London, GB); Sven Tiedemann (Lübeck, DE); Chun Jenny Siegfeld (Lübeck, DE)
Assignee: Tate & Lyle Solutions USA LLC
A23L27/36A23L2/385A23L2/44A23L2/60A23L2/68
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,295,395
App. No.
17/554,998
Granted
May 13, 2025
Kind
B2
Abstract

Provided herein is a liquid concentrate composition having steviol glycosides, a stabiliser including xanthan and/or iota-carrageenan, and water. The steviol glycosides include rebaudioside M in an amount of about 800 ppm or more by total weight of the liquid concentrate composition. The pH of the liquid concentrate composition is less than about 7. Also provided herein is a method of providing a food product, a food product obtainable from the method, and a method of providing a liquid concentrate composition.

Claims (22)

1. A liquid concentrate composition comprising:

steviol glycosides, wherein the steviol glycosides include rebaudioside M in an amount of about 800 ppm or more by total weight of the liquid concentrate composition;

a stabiliser comprising xanthan and/or iota-carrageenan; and water;

wherein the pH of the liquid concentrate composition is less than about 7.

2. The liquid concentrate composition of claim 1 , wherein the pH of the liquid concentrate composition is less than about 5.

3. The liquid concentrate composition of claim 1 , wherein the steviol glycosides are present in the liquid concentrate composition in an amount of about 1000 ppm or more by total weight of the liquid concentrate composition.

4. The liquid concentrate composition of claim 1 , wherein the steviol glycosides include rebaudioside M in an amount of at least about 50% by weight of the steviol glycosides.

5. The liquid concentrate composition of claim 1 , wherein the steviol glycosides include rebaudioside M in an amount of at least about 95% by weight of the steviol glycosides.

6. The liquid concentrate composition of claim 1 , wherein the liquid concentrate composition is a stable suspension at a temperature of less than about 45° C.

7. The liquid concentrate composition of claim 1 , wherein the stabiliser is present in the liquid concentrate composition in an amount of from about 0.01 to about 2.0% by total weight of the liquid concentrate composition.

8. The liquid concentrate composition of claim 1 , wherein the xanthan is present in the liquid concentrate composition in an amount of from about 0.01 to 1.0% by total weight of the liquid concentrate composition.

9. The liquid concentrate composition of claim 1 , wherein the iota-carrageenan is present in the liquid concentrate composition in an amount of from about 0.05 to 1.0% by total weight of the liquid concentrate composition.

10. The liquid concentrate composition of claim 1 , wherein the liquid concentrate composition comprises a food-compatible sequestering agent.

11. The liquid concentrate composition of claim 10 , wherein the food-compatible sequestering agent is present in the liquid concentrate composition in an amount of from about 0.01% to about 2.0% by total weight of the liquid concentrate composition.

12. The liquid concentrate composition of claim 10 , wherein the food-compatible sequestering agent is selected from the group consisting of trisodium citrate, sodiumhexametaphosphate, sodium acid pyrophosphate, trisodium phosphate, tetrasodium, pyrophosphate, sodium tripolyphosphate, disodium phosphate, ethylenediamine tetraacetic acid disodium salt, including corresponding conjugate acids, potassium salts, and mixtures thereof.

13. The liquid concentrate composition of claim 11 , wherein the food-compatible sequestering agent comprises trisodium citrate.

14. The liquid concentrate composition of claim 1 , wherein the liquid concentrate composition comprises a food-compatible acid selected from the group consisting of citric acid, phosphoric acid, malic acid, ascorbic acid, benzoic acid, lactic acid, fumaric acid, adipic acid, tartaric acid, gluconic acid, succinic acid, maleic acid, cinnamic acid, glutaric acid, or carbonic acid, and mixtures thereof.

15. The liquid concentrate composition of claim 14 , wherein the food-compatible acid is present in the liquid concentrate composition in an amount of from about 0.01 to about 2.5% by total weight of the liquid concentrate composition.

16. The liquid concentrate composition of claim 15 , wherein the food-compatible acid comprises citric acid.

17. The liquid concentrate composition of claim 1 , wherein the liquid concentrate composition has a viscosity of about 1 mPa's or greater.

18. The liquid concentrate composition of claim 1 , wherein the liquid concentrate composition has a global Turbiscan Stability Index of about 5 or less, after standing for 17 hours.

19. The liquid concentrate composition of claim 1 , wherein the liquid concentration composition has a global Turbiscan Stability Index of about 15 or less, after standing for 72 hours.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2022
From: TATE & LYLE INGREDIENTS AMERICAS LLC
To: TATE & LYLE SOLUTIONS USA LLC
Reel/Frame 059285/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2021
From: QUINLAN, MARY ELIZABETH; TIEDEMANN, SVEN; SIEGFELD, CHUN JENNY
To: TATE & LYLE INGREDIENTS AMERICAS LLC
Reel/Frame 058423/0382 →
Priority Claims (1)
GB 1908813 · Jun 19, 2019 · national
Continuity (2)
Continuation PCTGB2020051481 · Jun 18, 2020
Related Publication 20220125085A1 · Apr 28, 2022
References Cited (29)
US 10750760B2 · Woodall · 2020 [cited by applicant]
US 10905146B2 · Prakash et al. · 2021 [cited by applicant]
US 20140099403A1 · Prakash · 2014 [cited by examiner]
US 20140342043A1 · Bell · 2014 [cited by examiner]
US 20150017284A1 · Prakash · 2015 [cited by examiner]
US 20150086695A1 · Oglesby · 2015 [cited by examiner]
US 20160309761A1 · Brower, III et al. · 2016 [cited by applicant]
US 20170119032A1 · Patron · 2017 [cited by examiner]
US 20190133170A1 · Brijwani et al. · 2019 [cited by applicant]
US 20190223481A1 · Gaspard · 2019 [cited by examiner]
US 20200163874A1 · Chen · 2020 [cited by examiner]
US 20220162250A1 · Gaspard · 2022 [cited by examiner]
US 20220256900A1 · Sundaresan · 2022 [cited by examiner]
US 20230127708A1 · Gaspard · 2023 [cited by examiner]
CN 107529774A · 2016 [cited by applicant]
CN 105722533A · 2016 [cited by applicant]
JP 2016518143A · 2016 [cited by applicant]
WO 2013148177A1 · 2013 [cited by applicant]
WO 2014186084A1 · 2014 [cited by applicant]
WO 2015006764A1 · 2015 [cited by applicant]
WO 2016139470A1 · 2016 [cited by applicant]
WO 2019071182A1 · 2019 [cited by applicant]
WO 2019071188A1 · 2019 [cited by applicant]
Japanese Patent Office Office Action for JP Pat. Appl. No. 2021-575526, and partial translation, dispatched Apr. 3, 2024, 17 pages. [cited by applicant]
Chinese Office Action for Chinese Application No. 202080044753.6, dated May 19, 2023 with partial translation, 13 pages. [cited by applicant]
International Search Report and Written Opinion dated Nov. 2, 2020 for PCT Application No. PCT/GB2020/051481. [cited by applicant]
GB Search Report dated Nov. 18, 2019 for GB Application No. GB1908813.7. [cited by applicant]
Korean Notice of Non-Final Rejection for Application No. KR 1020227000054 with copies of references cited therein, mailed Mar. 10, 2025, 145 pages. [cited by applicant]
Partial English Translation of Korean Notice of Non-Final Rejection for Application No. KR 1020227000054, mailed Mar. 10, 2025, 5 pages. [cited by applicant]